Information on the Target
On June 12, 2023, Applus+, a distinguished leader in the testing, inspection, and certification (TIC) sector, announced its acquisition of Rescoll. Rescoll, founded in 2000 and headquartered in Bordeaux, France, is recognized as a premier materials testing and research and development technological partner. Employing 170 professionals, the company boasts an annual revenue of €21 million and is equipped with state-of-the-art laboratories.
Rescoll specializes in chemical analysis, mechanical testing, and material and process engineering, with particular emphasis on adhesives and coatings. The company enjoys a strong reputation in France, owing to its extensive and accredited testing portfolio, catering to vital industries such as medical, aerospace, energy, and general manufacturing.
Industry Overview in France
The testing and certification industry in France plays a crucial role in ensuring product quality and safety across various sectors, including aerospace, medical devices, and energy. Growth in these sectors is driven by increasing regulatory requirements and consumer demand for high-quality, safe, and environmentally sustainable products. The French government supports this industry through investments in research and development, aiming to boost innovation and maintain global competitiveness.
As a key player in the European market, France possesses numerous companies focusing on advanced materials and technologies essential for sectors such as medical devices and aerospace. This specialization has resulted in a burgeoning ecosystem of expertise, which enhances collaboration between academia, industry, and government, ultimately facilitating the development of innovative solutions.
Additionally, the push towards sustainability and the energy transition is transforming traditional practices within the industry. Companies are increasingly seeking testing and certification partners who can not only meet stringent regulatory standards but also provide expertise in developing environmentally-friendly materials and practices.
In this dynamic landscape, companies like Rescoll are well-positioned to thrive. Their accredited testing services align with the evolving needs of industries that prioritize safety, performance, and sustainability, ensuring that they remain competitive in both local and global markets.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
The Rationale Behind the Deal
Applus+'s acquisition of Rescoll is strategically timed, reinforcing its service offerings in response to the growing demands of the medical device and aerospace sectors. By integrating Rescoll's specialized capabilities, Applus+ is well-equipped to address the complexities of biocompatibility and mechanical testing for medical implants and biomaterials.
This acquisition dovetails with Applus+'s recent strategic initiatives, including the purchase of CFI, a leading Chinese automotive testing laboratory. Together, these investments underscore Applus+'s commitment to expanding its presence in high-growth markets and reinforcing its reputation as a comprehensive service partner across industries.
Information About the Investor
Applus+ is one of the world's most innovative companies in the TIC sector, committed to delivering quality, safety, and environmental solutions across diverse industries. The company is headquartered in Spain, operates in over 65 countries, and employs more than 26,000 people, reflecting its extensive capabilities and global reach.
For the fiscal year 2022, Applus+ reported significant financial performance, with a revenue of €2,050 million and an adjusted operating profit of €202 million. Applus+ is listed on the Spanish stock exchange and continually invests in developing proprietary solutions, holding 151 patents and managing over 210 active research projects. This commitment to innovation and sustainability positions Applus+ favorably in the market.
View of Dealert
The acquisition of Rescoll is viewed favorably given the growing emphasis on technological and certification services in the medical and aerospace sectors. By integrating Rescoll's specialized expertise, Applus+ diversifies and strengthens its service offerings, which is crucial in navigating the evolving landscape of regulatory standards and consumer expectations.
Moreover, the partnership allows Applus+ to enhance its capabilities in developing environmentally sustainable materials—an increasingly pressing requirement within industries facing regulatory pressures surrounding sustainability. This acquisition fundamentally aligns with Applus+'s strategic focus on higher-margin businesses, ensuring they remain competitive in the ever-changing market.
Looking ahead, the synergies created by this acquisition will likely foster innovation and expand Applus+'s service offerings significantly. The combined strengths of both companies may position them as a leading force in Europe for testing and certification services, providing a competitive edge and driving future growth.
In conclusion, Applus+'s acquisition of Rescoll is not only strategic but positions the company for sustained success. By bolstering its portfolio and expertise, Applus+ is poised to leverage emerging opportunities within key industries, representing a prudent investment with significant potential for growth.
Similar Deals
Edmond de Rothschild Equity Strategies IV SLP → M-Energies
2025
FIDUCIAL Expertise → Ariane, Sogeca Run, Neo Expert
2024
Applus+
invested in
Rescoll
in 2023
in a Buyout deal
Disclosed details
Revenue: $21M